SCHEMBL2803843

SCHEMBL2803843

Clc1ccc(CNc2ncc3c(n2)CCc2cnc4[nH]ncc4c2-3)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 3/20 0.42
CDK2 P24941 3/20 0.42
PLK4 O00444 1/20 0.41
PAK4 O96013 1/20 0.41
GRM5 P41594 2/20 0.38
RPS6KB1 P23443 4/20 0.38
NTRK1 P04629 1/20 0.37
IGF1R P08069 1/20 0.37
VNN1 O95497 1/20 0.36
LMNA P02545 2/20 0.36
MAPK1 P28482 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2804059 0.89 DYRK1A (0.48) RPS6KB1MAPK1MAOB
SCHEMBL2802228 0.88 AKT1 (0.38) CCNA2CDK2RPS6KB1LMNAMAPT
SCHEMBL2803917 0.83 ALDH1A1 (0.42) CCNA2CDK2PLK4PAK4RPS6KB1
SCHEMBL2802884 0.83 CDK2 (0.47) CCNA2CDK2IGF1RVNN1HDAC3
SCHEMBL2805133 0.82 RPS6KB1 (0.52) PLK4PAK4GRM5RPS6KB1NTRK1
SCHEMBL2802889 0.81 RPS6KB1 (0.43) CCNA2CDK2PLK4PAK4GRM5
SCHEMBL2806925 0.81 RPS6KB1 (0.39) CCNA2CDK2PLK4PAK4RPS6KB1
SCHEMBL2805136 0.80 LCK (0.41) CCNA2CDK2RPS6KB1MAPK1MAPT
SCHEMBL2805552 0.80 CCNA2 (0.44) CCNA2CDK2IGF1RHDAC3HDAC1
SCHEMBL2806333 0.79 RPS6KB1 (0.54) CCNA2CDK2RPS6KB1NTRK1IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 CCNA2 306/4885CDK2 46/4885PLK4 752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.